Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Morbi pulvinar augue lorem
Original price was: $78.00.$49.00Current price is: $49.00.Add to cartPhasellus massa felis, condimentum quis tortor mattis, condimentum varius eros. Vestibulum quis augue sem. Curabitur non vehicula elit, et cursus tortor. Quisque placerat velit nec nulla sodales, porttitor mattis tortor porta. Praesent gravida leo nibh, vel semper nulla lobortis vel. Donec nisl velit, iaculis ac dolor eget, blandit elementum urna.
-
Quick View
Cras viverra rhoncus metu
$77.00Add to cartAenean ut commodo justo. Fusce accumsan erat ut purus mollis, quis fermentum magna luctus. Morbi pulvinar augue lorem, quis molestie ipsum dictum non. Donec malesuada fermentum ex non hendrerit. Sed tempor viverra arcu a ultrices. Suspendisse non malesuada massa. Praesent imperdiet rhoncus nunc, vel fringilla enim lacinia quis
-
Quick View
Phasellus varius turpis
Original price was: $87.00.$76.00Current price is: $76.00.Add to cartFusce nec diam et dolor ornare rhoncus nec ut mauris. In eleifend mi in felis dictum fermentum. Morbi vel arcu sit amet dolor venenatis bibendum in eu dui. Nulla velit dolor, imperdiet consectetur luctus ut, faucibus eget est.
-
Quick View
Fusce nec diam et dolor
$45.00Add to cartFusce nec diam et dolor ornare rhoncus nec ut mauris. In eleifend mi in felis dictum fermentum. Morbi vel arcu sit amet dolor venenatis bibendum in eu dui. Nulla velit dolor, imperdiet consectetur luctus ut, faucibus eget est.
Reviews
There are no reviews yet.